ArticleFrontiers in aging neuroscience2025
LOU/c/jall rat as a model of resilience in the context of streptozotocin-induced cognitive impairment.
Article in Frontiers in aging neuroscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The concept of cognitive resilience (CR) has emerged to explain the lack of correlation between the extent of brain lesions and the severity of cognitive symptoms in Alzheimer's disease (AD), but the underlying mechanisms remain poorly understood. Methods: To investigate this, we developed a preclinical model of CR using a sporadic model of AD in a specific rat strain named LOU/c/jall described as a successful aging model. LOU/c/jall and Wistar control rats were bilaterally injected with streptozotocin (STZ; 3 mg/kg) or a vehicle solution into the cerebral ventricles. Cognitive performance and neuropathological examinations were evaluated 1 month after surgery. Results: Our results showed that STZ-injected Wistar exhibited greater cognitive deficits than LOU/c/jall, despite similar brain alterations, revealing for the first time CR in the LOU/c/jall strain. Proteomic analysis identified differentially expressed proteins involved in the AD pathway between the two strains. Discussion: Understanding the role of these proteins in AD could improve our understanding of the brain mechanisms underlying CR and guide the development of more targeted therapeutic strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.